EMA grants chikungunya vaccine program priority drug eligibility

chikungunya fever is an acute infectious disease caused by CHIKV, transmitted by the Aedes aegypti mosquito, characterized by fever, rash and joint pain, with long-term debilitating effects, and there is nodrug(and vaccines) to treat or preventChikungunya fever is currently sweeping across the Americas and the Caribbean, where more than 1.7 million cases of chikungunya fever have been reported in 45 countries over the past four years, most of them suffering from severe joint painRecently, the Austrian biotechnologycompanyannounced that the EuropeanMedicines(EMA) has granted priority drug qualification signed by the Chikungunya virus (CHIKV) vaccine, which is used to prevent chikungunya feverPRIME is a rapid review process for key drugs launched by EMA in March 2016, similar to the Breakthrough Therapeutics Identification (BTD) programthe U.SFDA, which aims to accelerate the review process forpharmaceutical(key drugs in the shortage area)The pilot drugs that shortlisted FOR PRIME will receive significant support from EMA in clinicaltrial(and drug development) to accelerate the development and approval of trulynew drugs to meet the demand formedical(demand) for promising new drugsIn clinical studies, Themis's candidate vaccine has shown excellent safety and immune response dataThe final results from the Phase II clinical study of large dose confirmation are expected to be available by mid-2018several additional Phase II clinical programs are under way, with more than 600 research volunteers from the United States, the European Union and Central America